Eton Pharmaceutcials Inc ETON

$61.36 -0.63 (-1.02%)

Valuation

Market cap
1,787,915,000
Revenue TTM
$79,950,000
Net income TTM
$-4,600,000
P/E (trailing)
42.15
P/E (forward)
41.33
Profit margin
-5.75%
Debt to equity
0.27

Trading

Volume
389,000
Avg volume
583,720
Day's range
$61.01 – $63.38
Shares out
28,842,000
Stochastic %K
32%
Beta
0.89
Analysts
Strong Buy
Price target
$71.90

Price

Company profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn...

Show more

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
847 787 7361
Website
https://www.etonpharma.com
Address
21925 W. Field Parkway, Suite 235, Deer Park, United States

Latest news

No headlines yet.